1
|
Behnagh AK, Eghbali M, Abdolmaleki F, Ghadikolaei OA, Asl PR, Afsharpad M, Cheraghi S, Honardoost M. An Overview on Prevalence and Detection Approaches of BRAF V600E Mutation in Anaplastic Thyroid Carcinoma: A Systematic Review and Meta-Analysis. IRANIAN JOURNAL OF PUBLIC HEALTH 2024; 53:1496-1507. [PMID: 39086414 PMCID: PMC11287593 DOI: 10.18502/ijph.v53i7.16044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/16/2023] [Accepted: 12/20/2023] [Indexed: 08/02/2024]
Abstract
Background BRAF V600E mutation is proved critical in the progression and invasion of thyroid cancer, and as a prognostic biomarker. As anaplastic thyroid cancer (ATC) is a rare and aggressive form of thyroid cancer, this study was conducted to provide a view on prevalence of BRAF V600E as well as the best molecular diagnostic method in ATC patients. Methods A comprehensive literature search was performed from their inception to Oct 2022 in PubMed, Scopus, Google Scholar, and Web of Science (WoS). The data of the prevalence of ATC were extracted. Moreover, the diagnostic feature of the available diagnostic tools was extracted to measure the sensitivity and specificity. To pool the prevalence data, we used meta-proportion analysis and diagnostic meta-analysis was conducted to determine the specificity and sensitivity of the immunohistochemistry method in detecting BRAF V600E mutation among patients with ATC. Results Overall, 34 studies were included in this meta-analysis. The incidence of BRAF V600E was shown 33% in the 978 patients. The sensitivity and specificity of IHC in detecting BRAF V600E were detected 78.9% (95%CI: 60.1-97.2), and 69.7% (95%CI: 41.2-98.1), respectively. Conclusion IHC had an acceptable prognostic profile for detecting BRAF V600E in ATC patients. The diagnosis of BRAF mutation is critical in clinical trials and may be helpful for choosing proper-targeted therapy strategies in ATC patients.
Collapse
Affiliation(s)
- Arman Karimi Behnagh
- Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
| | - Maryam Eghbali
- Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
| | - Fereshteh Abdolmaleki
- Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
| | - Omolbanin Asadi Ghadikolaei
- Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
| | - Parisa Rezazadeh Asl
- Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
| | - Mandana Afsharpad
- Cancer Control Research Center, Cancer Control Foundation, Iran University of Medical Sciences, Tehran, Iran
| | - Sara Cheraghi
- Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
| | - Maryam Honardoost
- Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
2
|
Martins-de-Barros AV, da Costa Araújo FA, Barros AMI, Dos Santos EGF, Barbosa Neto AG, da Silva HAM, de Lima ELS, Muniz MTC, Neves RFSN, de Hollanda Valente RO, de Oliveira E Silva ED, de Vasconcelos Carvalho M. It was not possible to detect BRAF V600E mutation in circulating cell-free DNA from patients with ameloblastoma: A diagnostic accuracy study. J Oral Pathol Med 2024; 53:258-265. [PMID: 38494749 DOI: 10.1111/jop.13529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Revised: 01/30/2024] [Accepted: 03/05/2024] [Indexed: 03/19/2024]
Abstract
BACKGROUND The objective of this study is to evaluate the diagnostic accuracy of plasma-based liquid biopsy for the detection of the BRAF V600E mutation in circulating cell-free DNA from patients with ameloblastoma. METHODS This is a prospective diagnostic accuracy study conducted based on the Standards for Reporting Diagnostic Accuracy recommendations. The index test was the plasma-based liquid biopsy, whereas the reference standard was the conventional tissue biopsy. The target condition was the detection of BRAF V600E mutation. The study population consisted of individuals with ameloblastoma recruited from three tertiary hospitals from Brazil. A negative control group composed of three individuals with confirmed wild-type BRAF lesions were included. The participants underwent plasma circulating cell-free DNA and tumor tissue DNA isolation, and both were submitted to using competitive allele-specific TaqMan™ real-time polymerase chain reaction technology mutation detection assays. Sensitivity and specificity measures and positive and negative predictive values were calculated. RESULTS Twelve patients with conventional ameloblastoma were included. BRAF V600E mutation was detected in 11/12 (91.66%) ameloblastoma tissue samples. However, the mutation was not detected in any of the plasma-based liquid biopsy circulating cell-free DNA samples in both ameloblastomas and negative control group. The sensitivity and specificity of plasma-based liquid biopsy for the detection of the BRAF V600E mutation in circulating cell-free DNA was 0.0 and 1.0, respectively. The agreement between index test and reference standard results was 26.66%. CONCLUSION Plasma-based liquid biopsy does not seem to be an accurate method for the detection of the BRAF V600E mutation in circulating circulating cell-free DNA from patients with ameloblastoma, regardless of tumor size, anatomic location, recurrence status, and other clinicopathological features.
Collapse
Affiliation(s)
- Allan Vinícius Martins-de-Barros
- School of Dentistry, Post-Graduation Program in Dentistry, University of Pernambuco (UPE), Recife, Pernambuco, Brazil
- Centro Integrado de Anatomia Patológica (CIAP), Hospital Universitário Oswaldo Cruz (HUOC/UPE), Recife, Pernambuco, Brazil
| | - Fábio Andrey da Costa Araújo
- School of Dentistry, Post-Graduation Program in Dentistry, University of Pernambuco (UPE), Recife, Pernambuco, Brazil
- Department of Oral and Maxillofacial Surgery, Hospital Universitário Oswaldo Cruz (HUOC/UPE), Recife, Pernambuco, Brazil
| | - Ana Maria Ipólito Barros
- School of Dentistry, Post-Graduation Program in Dentistry, University of Pernambuco (UPE), Recife, Pernambuco, Brazil
- Centro Integrado de Anatomia Patológica (CIAP), Hospital Universitário Oswaldo Cruz (HUOC/UPE), Recife, Pernambuco, Brazil
| | | | - Adauto Gomes Barbosa Neto
- Instituto de Ciências Biológicas (ICB/UPE), University of Pernambuco (UPE), Recife, Pernambuco, Brazil
| | | | - Elker Lene Santos de Lima
- Instituto de Ciências Biológicas (ICB/UPE), University of Pernambuco (UPE), Recife, Pernambuco, Brazil
| | | | | | | | - Emanuel Dias de Oliveira E Silva
- School of Dentistry, Post-Graduation Program in Dentistry, University of Pernambuco (UPE), Recife, Pernambuco, Brazil
- Department of Oral and Maxillofacial Surgery, Hospital Universitário Oswaldo Cruz (HUOC/UPE), Recife, Pernambuco, Brazil
| | - Marianne de Vasconcelos Carvalho
- School of Dentistry, Post-Graduation Program in Dentistry, University of Pernambuco (UPE), Recife, Pernambuco, Brazil
- Centro Integrado de Anatomia Patológica (CIAP), Hospital Universitário Oswaldo Cruz (HUOC/UPE), Recife, Pernambuco, Brazil
| |
Collapse
|
3
|
Romano C, Martorana F, Pennisi MS, Stella S, Massimino M, Tirrò E, Vitale SR, Di Gregorio S, Puma A, Tomarchio C, Manzella L. Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer. Int J Mol Sci 2021; 22:7707. [PMID: 34299334 PMCID: PMC8303548 DOI: 10.3390/ijms22147707] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Revised: 07/09/2021] [Accepted: 07/12/2021] [Indexed: 12/17/2022] Open
Abstract
Thyroid cancer is the most common malignancy of the endocrine system, encompassing different entities with distinct histological features and clinical behavior. The diagnostic definition, therapeutic approach, and follow-up of thyroid cancers display some controversial aspects that represent unmet medical needs. Liquid biopsy is a non-invasive approach that detects and analyzes biological samples released from the tumor into the bloodstream. With the use of different technologies, tumor cells, free nucleic acids, and extracellular vesicles can be retrieved in the serum of cancer patients and valuable molecular information can be obtained. Recently, a growing body of evidence is accumulating concerning the use of liquid biopsy in thyroid cancer, as it can be exploited to define a patient's diagnosis, estimate their prognosis, and monitor tumor recurrence or treatment response. Indeed, liquid biopsy can be a valuable tool to overcome the limits of conventional management of thyroid malignancies. In this review, we summarize currently available data about liquid biopsy in differentiated, poorly differentiated/anaplastic, and medullary thyroid cancer, focusing on circulating tumor cells, circulating free nucleic acids, and extracellular vesicles.
Collapse
Affiliation(s)
- Chiara Romano
- Center of Experimental Oncology and Hematology, A.O.U. Policlinico “G. Rodolico—San Marco”, 95123 Catania, Italy; (C.R.); (F.M.); (M.S.P.); (S.S.); (M.M.); (E.T.); (S.R.V.); (S.D.G.); (A.P.); (C.T.)
- Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
| | - Federica Martorana
- Center of Experimental Oncology and Hematology, A.O.U. Policlinico “G. Rodolico—San Marco”, 95123 Catania, Italy; (C.R.); (F.M.); (M.S.P.); (S.S.); (M.M.); (E.T.); (S.R.V.); (S.D.G.); (A.P.); (C.T.)
- Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
| | - Maria Stella Pennisi
- Center of Experimental Oncology and Hematology, A.O.U. Policlinico “G. Rodolico—San Marco”, 95123 Catania, Italy; (C.R.); (F.M.); (M.S.P.); (S.S.); (M.M.); (E.T.); (S.R.V.); (S.D.G.); (A.P.); (C.T.)
- Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
| | - Stefania Stella
- Center of Experimental Oncology and Hematology, A.O.U. Policlinico “G. Rodolico—San Marco”, 95123 Catania, Italy; (C.R.); (F.M.); (M.S.P.); (S.S.); (M.M.); (E.T.); (S.R.V.); (S.D.G.); (A.P.); (C.T.)
- Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
| | - Michele Massimino
- Center of Experimental Oncology and Hematology, A.O.U. Policlinico “G. Rodolico—San Marco”, 95123 Catania, Italy; (C.R.); (F.M.); (M.S.P.); (S.S.); (M.M.); (E.T.); (S.R.V.); (S.D.G.); (A.P.); (C.T.)
- Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
| | - Elena Tirrò
- Center of Experimental Oncology and Hematology, A.O.U. Policlinico “G. Rodolico—San Marco”, 95123 Catania, Italy; (C.R.); (F.M.); (M.S.P.); (S.S.); (M.M.); (E.T.); (S.R.V.); (S.D.G.); (A.P.); (C.T.)
- Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, 90127 Palermo, Italy
| | - Silvia Rita Vitale
- Center of Experimental Oncology and Hematology, A.O.U. Policlinico “G. Rodolico—San Marco”, 95123 Catania, Italy; (C.R.); (F.M.); (M.S.P.); (S.S.); (M.M.); (E.T.); (S.R.V.); (S.D.G.); (A.P.); (C.T.)
- Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
| | - Sandra Di Gregorio
- Center of Experimental Oncology and Hematology, A.O.U. Policlinico “G. Rodolico—San Marco”, 95123 Catania, Italy; (C.R.); (F.M.); (M.S.P.); (S.S.); (M.M.); (E.T.); (S.R.V.); (S.D.G.); (A.P.); (C.T.)
- Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
| | - Adriana Puma
- Center of Experimental Oncology and Hematology, A.O.U. Policlinico “G. Rodolico—San Marco”, 95123 Catania, Italy; (C.R.); (F.M.); (M.S.P.); (S.S.); (M.M.); (E.T.); (S.R.V.); (S.D.G.); (A.P.); (C.T.)
- Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
| | - Cristina Tomarchio
- Center of Experimental Oncology and Hematology, A.O.U. Policlinico “G. Rodolico—San Marco”, 95123 Catania, Italy; (C.R.); (F.M.); (M.S.P.); (S.S.); (M.M.); (E.T.); (S.R.V.); (S.D.G.); (A.P.); (C.T.)
- Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
| | - Livia Manzella
- Center of Experimental Oncology and Hematology, A.O.U. Policlinico “G. Rodolico—San Marco”, 95123 Catania, Italy; (C.R.); (F.M.); (M.S.P.); (S.S.); (M.M.); (E.T.); (S.R.V.); (S.D.G.); (A.P.); (C.T.)
- Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
| |
Collapse
|
4
|
Miller KC, Chintakuntlawar AV. Molecular-Driven Therapy in Advanced Thyroid Cancer. Curr Treat Options Oncol 2021; 22:24. [PMID: 33569661 DOI: 10.1007/s11864-021-00822-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/11/2021] [Indexed: 01/02/2023]
Abstract
OPINION STATEMENT With a growing understanding of the biologic drivers of different thyroid cancers, there is an ongoing revolution in the treatment of aggressive and advanced disease variants. This includes matching patients with specific point mutations or gene fusions to targeted therapies (e.g., selective RET inhibitors), delineating patients who are likely to respond to immune checkpoint inhibition (i.e., PD-L1-positive tumors) and even priming responses to traditional therapies such as radioactive iodine (via concomitant MAPK pathway inhibition). There is also a growing role for genomics in the prognostication of thyroid tumors to aid the adjudication of appropriate treatments. Taking stock of the current state of the field, recent successes should be celebrated, but there still remains a long road ahead to improve outcomes for patients, particularly for radioactive-iodine refractory differentiated thyroid cancer and anaplastic thyroid cancer. In this review, we summarize findings from recent clinical trials and highlight promising preclinical data supporting molecular-driven therapy in advanced thyroid cancer. Ultimately, enrollment in clinical trials remains paramount to the advancement of thyroid cancer care.
Collapse
Affiliation(s)
- Kevin C Miller
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
| | | |
Collapse
|
5
|
Pogliaghi G. Liquid biopsy in thyroid cancer: from circulating biomarkers to a new prospective of tumor monitoring and therapy. Minerva Endocrinol (Torino) 2020; 46:45-61. [PMID: 33213118 DOI: 10.23736/s2724-6507.20.03339-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Recently, liquid biopsy has attracted much interest as a tool for early cancer screening, prognosis, monitoring and response to treatment in many different cancer types. Indeed, liquid biopsies can be repeatedly performed in a noninvasive way, at lower cost and without the risks associated to the classic tissue biopsy. The objective of this monography was to describe the main components studied in liquid biopsy (circulating tumor nucleic acids, circulating tumor cells and extracellular vesicles) and how they have been explored in thyroid cancer, through an in-depth scientific literature review. While circulating tumor cells are the most represented component in the literature of liquid biopsy in thyroid cancer, circulating tumor nucleic acids and extracellular vesicles have also been recently explored. One important challenge in this field of research, especially for differentiated thyroid cancer, has been the low quantity of circulating components with respect to other cancer types, requiring more advanced techniques for both isolation and analysis. Despite these limitations, liquid biopsy showed promise as an additional noninvasive tool for diagnosis, prognosis, to predict outcome and therapeutic response in differentiated, medullary and anaplastic thyroid cancer.
Collapse
Affiliation(s)
- Gabriele Pogliaghi
- Division of Endocrine and Metabolic Research, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Milan, Italy -
| |
Collapse
|